PD-1/PD-L1信号通路在食管鳞状细胞癌中的研究进展
Research Progress of PD-1/PD-L1 Signaling Pathway in Esophageal Squamous Cell Carcinoma
DOI: 10.12677/ACM.2023.13102347, PDF,   
作者: 图荪阿依·吾麦尔, 苏晓梅, 马晓梅*:新疆医科大学第三临床医学院(附属肿瘤医院)病理科,新疆 乌鲁木齐
关键词: 食管鳞状细胞癌免疫治疗PD-1PD-L1Esophageal Squamous Cell Carcinoma Immunotherapy PD-1 PD-L1
摘要: 程序性细胞死亡-1 (PD-1)和程序性死亡配体1 (PD-L1)是维持免疫稳态的重要蛋白,在生理情况下,PD-1/PD-L1信号通路介导且参与外周自身耐受性的维持和自身免疫性疾病的预防,在肿瘤微环境(TME)中,肿瘤细胞可以通过在细胞表面表达PD-L1并与PD-1受体阳性的免疫效应细胞结合,使PD-L1表达水平向上调节,致肿瘤细胞能够躲避被免疫识别与攻击。PD-1/PD-L1信号通路抑制剂可以特异性阻断PD-1与PD-L1之间结合,激活T细胞活性,对肿瘤细胞产生杀伤力。本文的目的是阐述PD-1/PD-L1信号通路在食管鳞状细胞癌中的研究成果及临床意义,回顾现有的临床证据,为食管鳞状细胞癌的治疗提供最新知识。
Abstract: Programmed cell death-1 (PD-1) and programmed death ligand 1 (PD-L1) are important proteins in the maintenance of immune homeostasis. Under physiological conditions, PD-1/PD-L1 signaling pathway mediates and participates in the maintenance of peripheral autotolerance and the pre-vention of autoimmune diseases. Tumor cells can express PD-L1 on the cell surface and bind to PD-1 receptor-positive immune effector cells, so that the expression level of PD-L1 can be adjusted up-ward, so that tumor cells can avoid immune recognition and attack. PD-1/PD-L1 signaling pathway inhibitors can specifically block the binding between PD-1 and PD-L1, activate T cell activity, and cause damage to tumor cells. The purpose of this paper is to expound the research results and clin-ical significance of PD-1/PD-L1 signaling pathway in esophageal squamous cell carcinoma, and re-view the existing clinical evidence, to provide the latest knowledge in the treatment of esophageal squamous cell carcinoma.
文章引用:图荪阿依·吾麦尔, 苏晓梅, 马晓梅. PD-1/PD-L1信号通路在食管鳞状细胞癌中的研究进展[J]. 临床医学进展, 2023, 13(10): 16766-16771. https://doi.org/10.12677/ACM.2023.13102347

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Liang, M.-Q., Yu, F.-Q. and Chen, C. (2020) C-Myc Regulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma. American Journal of Translational Research, 12, 379-388.
[3] Lu, D., Liu, X., Feng, S., et al. (2019) The Current Situation of Esophageal Cancer Staging and Perioper-ative Strategies Determination in Central and Southern China: A Cross Sectional Survey. Frontiers in Oncology, 9, Arti-cle No. 1098. [Google Scholar] [CrossRef] [PubMed]
[4] Liu, W., Huo, G. and Chen, P. (2023) Efficacy of PD-1/PD-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis. Immuno-therapy, 15, 751-771. [Google Scholar] [CrossRef] [PubMed]
[5] Dedecker, H., Teuwen, L.-A., Vandamme, T., et al. (2023) The Role of Immunotherapy in Esophageal and Gastric Cancer. Clinical Colorectal Cancer, 22, 175-182. [Google Scholar] [CrossRef] [PubMed]
[6] Yi, M., Niu, M., Xu, L., et al. (2021) Regulation of PD-L1 Expres-sion in the Tumor Microenvironment. Journal of Hematology & Oncology, 14, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[7] Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377, 1345-1356. [Google Scholar] [CrossRef
[8] Kudo, T., Hamamoto, Y., Kato, K., et al. (2017) Nivolumab Treat-ment for Oesophageal Squamous-Cell Carcinoma: An Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 18, 631-639. [Google Scholar] [CrossRef
[9] Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) Check-Mate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab plus Ipilimumab in Patients with Metastatic Esoph-agogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. [Google Scholar] [CrossRef
[10] Kojima, T., Muro, K., Francois, E., et al. (2019) Pembrolizumab versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer: Phase III KEYNOTE-181 Study. Journal of Clinical Oncology, 37, 2. [Google Scholar] [CrossRef
[11] Garon, E.B., Hellmann, M.D., Rizvi, N.A., et al. (2019) Five-Year Overall Survival for Patients with Advanced Non‒Small-Cell Lung Cancer Treated with Pembrolizumab: Re-sults from the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527. [Google Scholar] [CrossRef
[12] Hamid, O., Robert, C., Daud, A., et al. (2019) Five-Year Survival Outcomes for Patients with Advanced Melanoma Treated with Pembrolizumab in KEYNOTE-001. Annals of Oncology, 30, 582-588. [Google Scholar] [CrossRef] [PubMed]
[13] Ishida, Y., Agata, Y., Shibahara, K., et al. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death. The EMBO Jour-nal, 11, 3887-3895. [Google Scholar] [CrossRef] [PubMed]
[14] Carreno, B.M. and Collins, M. (2002) The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses. Annual Review of Immunology, 20, 29-53. [Google Scholar] [CrossRef] [PubMed]
[15] Ratajczak, K., Grel, H., Olejnik, P., et al. (2023) Current Progress, Strategy, and Prospects of PD-1/PDL-1 Immune Checkpoint Biosensing Platforms for Cancer Diag-nostics, Therapy Monitoring, and Drug Screening. Biosensors and Bioelectronics, 240, Article ID: 115644. [Google Scholar] [CrossRef] [PubMed]
[16] Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
[17] Yang, Q., Shi, G., Chen, X., et al. (2020) Nanomicelle Protects the Immune Activation Effects of Paclitaxel and Sensitizes Tumors to Anti-PD-1 Immuno-therapy. Theranostics, 10, 8382-8399. [Google Scholar] [CrossRef] [PubMed]
[18] Sudo, S., Kajiya, H., Okano, S., et al. (2020) Cisplatin-Induced Programmed Cell Death Ligand-2 Expression Is Associated with Metastasis Ability in Oral Squamous Cell Carcinoma. Cancer Science, 111, 1113-1123. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, X., Ke, X., Ni, Y., et al. (2020) Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Journal of Immunology Research, 2020, Article ID: 8884683. [Google Scholar] [CrossRef] [PubMed]
[20] Lantuejoul, S., Damotte, D., Hofman, V., et al. (2019) Programmed Death Ligand 1 Immunohistochemistry in Non-Small Cell Lung Carcinoma. Journal of Thoracic Disease, 11, S89-S101. [Google Scholar] [CrossRef] [PubMed]
[21] Cui, Y., Shi, J., Cui, Y., et al. (2023) The Relationship between Au-tophagy and PD-L1 and Their Role in Antitumor Therapy. Frontiers in Immunology, 14, Article ID: 1093558. [Google Scholar] [CrossRef] [PubMed]
[22] Lv, G., Sun, X., Qiu, L., et al. (2020) PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Journal of Nuclear Medicine, 61, 117-122. [Google Scholar] [CrossRef] [PubMed]
[23] Shi, F., Shi, M., Zeng, Z., et al. (2011) PD-1 and PD-L1 Upregulation Promotes CD8+ T-Cell Apoptosis and Postoperative Recurrence in Hepatocellular Carcinoma Patients. In-ternational Journal of Cancer, 128, 887-896. [Google Scholar] [CrossRef] [PubMed]
[24] Patsoukis, N., Sari, D. and Boussiotis, V.A. (2012) PD-1 Inhibits T Cell Proliferation by Upregulating p27 and p15 and Suppressing Cdc25A. Cell Cycle, 11, 4305-4309. [Google Scholar] [CrossRef] [PubMed]
[25] Mansfield, A.S., Aubry, M.C., Moser, J.C., et al. (2016) Temporal and Spa-tial Discordance of Programmed Cell Death-Ligand 1 Expression and Lymphocyte Tumor Infiltration between Paired Primary Lesions and Brain Metastases in Lung Cancer. Annals of Oncology, 27, 1953-1958. [Google Scholar] [CrossRef] [PubMed]
[26] Velcheti, V., Rimm, D.L. and Schalper, K.A. (2013) Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal of Thoracic Oncology, 8, 803-805. [Google Scholar] [CrossRef
[27] Rollins, M.R. and Gibbons Johnson, R.M. (2017) CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells. Journal of Im-munology Research, 2017, e7659462. [Google Scholar] [CrossRef] [PubMed]
[28] Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. [Google Scholar] [CrossRef] [PubMed]
[29] Cheng, C., Zhuge, L., Xiao, X., et al. (2022) Overcoming Resistance to PD-1/PD-L1 Inhibitors in Esophageal Cancer. Frontiers in Oncology, 12, Article No. 955163. [Google Scholar] [CrossRef] [PubMed]
[30] Hu, C., Meiners, S., Lukas, C., et al. (2020) Role of Exosomal mi-croRNAs in Lung Cancer Biology and Clinical Applications. Cell Proliferation, 53, e12828. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, K., Cheng, G., Zhang, F., et al. (2016) Prognostic Significance of Programmed Death-1 and Programmed Death-Ligand 1 Expression in Patients with Esophageal Squamous Cell Carci-noma. Oncotarget, 7, 30772-30780. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, Z., Sun, L., Cai, L., et al. (2022) Clinicopathological and Prog-nostic Values of PD-L1 Expression in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis of 31 Studies with 5368 Patients. Postgraduate Medical Journal, 98, 948-957. [Google Scholar] [CrossRef] [PubMed]
[33] Jesinghaus, M., Steiger, K., Slotta-Huspenina, J., et al. (2017) In-creased Intraepithelial CD3+ T-Lymphocytes and High PD-L1 Expression on Tumor Cells Are Associated with a Fa-vorable Prognosis in Esophageal Squamous Cell Carcinoma and Allow Prognostic Immunogenic Subgrouping. Onco-target, 8, 46756-46768. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, W., Pang, Q., Zhang, X., et al. (2017) Programmed Death-Ligand 1 Is Prognostic Factor in Esophageal Squamous Cell Carcinoma and Is Associated with Epidermal Growth Factor Receptor. Cancer Science, 108, 590-597. [Google Scholar] [CrossRef] [PubMed]
[35] Jiang, Y., Chen, M., Nie, H., et al. (2019) PD-1 and PD-L1 in Cancer Im-munotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122. [Google Scholar] [CrossRef] [PubMed]
[36] Doki, Y., Ajani, J.A., Kato, K., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 386, 449-462. [Google Scholar] [CrossRef] [PubMed]
[37] Kato, K., Cho, B.C., Takahashi, M., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Pre-vious Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 1506-1517. [Google Scholar] [CrossRef
[38] Shah, M.A., Kojima, T., Hochhauser, D., et al. (2019) Effi-cacy and Safety of Pembrolizumab for Heavily Pretreated Patients with Advanced, Metastatic Adenocarcinoma or Squa-mous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncology, 5, 546-550. [Google Scholar] [CrossRef] [PubMed]
[39] Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 4138-4148. [Google Scholar] [CrossRef
[40] Sun, J.-M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. [Google Scholar] [CrossRef